Roche/Genentech Anti-Myostatin Adnectin RG6206 in Duchenne (May 2018)

Roche/Genentech joined Parent Project Muscular Dystrophy for a webinar on May 16, 2018 to provide an update on their Anti-Myostatin Adnectin (RG6206) development program. Learn more about the team at Roche and its US affiliate, Genentech, and how they are collaborating with the Duchenne community. The team also updated the community on their Anti-Myostatin Adnectin (RG6206) program, including the status of ongoing clinical studies.